BMY•benzinga•
Bristol Myers Squibb Releases Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy As An Adjunctive Treatment to Atypical Antipsychotics In Adults With Schizophrenia
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 22, 2025 by benzinga